Atara Biotherapeutics (NASDAQ:ATRA) Price Target Raised to $21.00

Atara Biotherapeutics (NASDAQ:ATRA) had its price target lifted by Canaccord Genuity Group from $13.00 to $21.00 in a report published on Wednesday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biotechnology company’s stock.

Several other analysts also recently weighed in on the company. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their target price for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. Finally, The Goldman Sachs Group decreased their target price on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research report on Wednesday, July 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $16.67.

Atara Biotherapeutics Stock Down 6.0 %

Shares of ATRA opened at $12.00 on Wednesday. The company has a market cap of $69.12 million, a PE ratio of -0.47 and a beta of 0.50. The business has a fifty day moving average of $9.00 and a 200 day moving average of $10.28. Atara Biotherapeutics has a 52-week low of $6.50 and a 52-week high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same quarter in the prior year, the business earned ($16.50) earnings per share. As a group, research analysts anticipate that Atara Biotherapeutics will post -12.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

Several institutional investors have recently made changes to their positions in the company. Redmile Group LLC increased its stake in shares of Atara Biotherapeutics by 1.7% during the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after buying an additional 156,863 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Atara Biotherapeutics by 8,916.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after buying an additional 4,903,159 shares during the period. Acadian Asset Management LLC increased its stake in shares of Atara Biotherapeutics by 49.5% during the first quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock valued at $1,830,000 after buying an additional 873,133 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Atara Biotherapeutics by 29.3% during the first quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after buying an additional 86,842 shares during the period. Finally, Vestal Point Capital LP increased its stake in shares of Atara Biotherapeutics by 11.3% during the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 12,677 shares during the period. Hedge funds and other institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.